Biology Reference
In-Depth Information
bioavailability - percentage of the dose that is measurable in
the circulation after extravascular (e.g., SC) administration.
True estimates are obtained in an IV/SC cross-over study using
the same dose wherein F = 100*(AUC
SC
/AIC
IV
)
F
FasL
Fas activity ligand
FDA
Food and Drug Administration
FH4
tetrahydrofolate
FIV
feline immunodeficiency virus
FmuLV
Friend murine leukemia virus
G0
period of cell cycle without perceived growth or replication
G1
period of cell cycle characterized by rapid protein synthesis
GATA-1
erythroid transcription factor
G-CSF
granulocyte colony-stimulating factor
GHR
growth hormone receptor
GM-CSF
granulocyte-macrophage colony-stimulating factor
GMP
good manufacturing practice
HCP
hematopoietic cell phosphatase
HIF-1
hyporxia-inducible factor-1
HIV
human immunodeficiency virus
ICAM
intercellular adhesion molecule
IFN
interferon
IGF
insulin-like growth factor
IL
interleukin
IOC
International Olympic Committee
IP
intraperitoneal, intraperitoneally
IRS
insulin receptor substrate
IV
intravenous, intravenously
JAK
Janus kinase
K
m
plasma concentration at which half-maximal effect is observed
Kd
kilodalton
LN
natural logarithm
MAT
mean absorption time - average time a molecule remains at
absorption site. Calculated from 1/K
a
MCH
mean corpuscular hemoglobin
MCV
mean corpuscular volume
MDS
myelodysplastic syndromes
MHC
major histocapatability complex
MRT
mean residence time. After IV dosing, it is the average time a
molecule remains in circulation. After SC or IP dosing, it is the
sum of the mean absorption time (MAT) and the average time
a molecule remains in the circulation. Calculated from moment
theory as AUMC
2
/AUC
